Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
      Description

      This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas

      Conditions
      LGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous T-Cell Lymphoma - CategoryPrimary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell LymphomaHepatosplenic T-cell LymphomaSubcutaneous Panniculitis-Like T-Cell LymphomaAggressive NK Cell LeukemiaSystemic EBV1 T-cell Lymphoma, if CD8 PositiveHydroa Vacciniforme-Like Lymphoproliferative DisorderExtranodal NK/T Cell Lymphoma, Nasal TypeEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaIndolent Chronic Lymphoproliferative Disorder (CLPD) (CD8+ or NK Derived) of the GI TractOther CD8+/NK Cell Driven Lymphoma Not Listed Above
      Talk to us
      ACTIVE_NOT_RECRUITING
      Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
      Description

      The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).

      Conditions
      Large Granular Lymphocyte Leukemia
      Talk to us
      COMPLETED
      Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients with Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
      Description

      This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L), T-cell prolymphocytic leukemia (T-PLL), and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), LGL-L, and solid tumors.

      Conditions
      Non Hodgkin Lymphoma (NHL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-Cell Lymphoma (CTCL)Large Granular Lymphocytic Leukemia (LGL-L)T-cell Prolymphocytic Leukemia (T-PLL)Solid Tumors
      Talk to us
      ACTIVE_NOT_RECRUITING
      ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
      Description

      An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

      Conditions
      T-cell Large Granular Lymphocytic Leukemia
      Talk to us